Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has
high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can
reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular
pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of
blood-brain barrier. Clinical studies have also shown that minocycline can significantly
improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale
(mRS) of patients with ischemic stroke, indicating that minocycline is a potential
neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby
reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether
minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no
clinical research in this area at present. Therefore, investigators carry out the study on
the effect of minocycline in patients with acute anterior circulation ischemic stroke after
mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and
effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.
Phase:
Phase 4
Details
Lead Sponsor:
Xijing Hospital
Collaborators:
First People's Hospital of Xianyang Xi'an Gaoxin Hospital Xi'an No.3 Hospital Xi'an XD Group Hospital